Pseudomyxoma Peritonei

Czech version

Authors: Petr Bartoška ¹; František Antoš ¹; Pavel Vítek ²; Josef Marx ¹; Jiří Kopic ¹; Petra Holečková ³
Authors‘ workplace: Chirurgická klinika 1. LF UK a Nemocnice Na Bulovce, Praha ¹; Protonové centrum, Praha ²; Ústav radiační onkologie, 1. LF UK a Nemocnice Na Bulovce, Praha ³
Published in: Klin Onkol 2019; 32(5): 329-332
Category: Review
doi: https://doi.org/10.14735/amko2019329

Overview

Background: Pseudomyxoma peritonei is a rare tumorous disease with various grades of malignancy and is characterized by production of mucinous and gelatinous masses. Development of pseudomyxoma peritonei is usually associated with rupture of appendiceal mucinous tumors and other mucinous tumors of the gastrointestinal tract or ovaries. Pseudomyxoma peritonei is usually divided into three types: low-grade, high-grade, and high-grade with signet ring cells. Staging of the disease is determined by the peritoneal cancer index. Clinical findings are highly variable depending on disease staging. The typical finding of “jelly belly” syndrome worsens with disease progression. The diagnosis is based on the pre-operative cure by imaging methods, especially computed tomography.

Methods: The Sugarbaker method involves maximal removal of tumorous masses, so-called cytoreductive surgery, and perioperative intraabdominal application of hot cytostatics (hyperthermic intraperitoneal chemotherapy) with the aim of achieving maximal liquidation of tumorous processes.

Results: Our results are comparable with previous published data and confirm high effectivness of this method. The results show statistically very significant extention of overall survival, disease free interval with acceptable lethality 0–12 % and morbidity 27–56%. These results promote this method as the gold standard of treatment of pseudomyxoma peritonei in selected patients.

Keywords:

cytoreductive surgery – pseudomyxoma peritonei – PCI – hypertermic intraperitoneal chemotherapy – HIPEC

Sources

1. Antoš F, Petr Dytrych P. Peritoneální nádory. Chirurgická onkologie. Praha: Grada publishing 2014: 601–613.

2. Baratti D, Kusamura S, Nonaka D et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2008; 15 (2): 526–534. doi: 10.1245/s10434-007-9691-2.

3. Kocián R. Pseudomyxoma peritonei. Actual Gyn 2013; 5: 10–13.

4. AJCC Cancer staging manual. 8th ed. New York: Springer 2017: 237–239.

5. Carr NJ, Cecil TD, Mohamed F et al. Consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified delphi process. Am J Surg Pathol 2016; 40 (1): 14–26. doi: 10.1097/PAS.0000000000000535.

6. Antoš F. Léčení diseminovaných nádorů dutiny břišní pomocí peritonektomie a peroperační hypertermické chemoterapie s možností profylaktického užití u kolorektálních karcinomů – závěrečná zpráva grantového projektu. IGA MZ ČR NR 8414/5.

7. Antoš F, Vítek P, Kopic J et al. Cytoreduktivní chirurgie a hypertermická peroperativní chemoterapie (HIPEC) v léčbě malignit peritoneálních povrchů. Onkologická Revue 2018; 5 (2): 62–67.

8. Dineen SP, Royal RE, Hughes MS et al. A simplified preoperative assessment predicts complete cytoreduction and outcomes in patients with low-grade mutinous adenocarcinoma of the appendix. Ann Surg Oncol 2015; 22 (11): 3640–3646. doi: 10.1245/s10434-015-4446-y.

9. Flicek K, Ashfaq A, Johnson CD. Correlation of radiologic with surgical peritoneal cancer index scores in patients with pseudomyxoma peritonei and peritoneal carcinomatosis: how well can we predict resectability? J Gastrointest Surg 2016; 20 (2): 307–312. doi: 10.1007/s11605-015-2880-6.

10. Canbay E, Ishibashi H, Sako S et al. Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg 2013; 37 (6): 1271–1276. doi: 10.1007/s00268-013-1988-7.

11. Kusamura S, Baratti D, Hutanu I et al. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 2015; 41 (8): 1097–1105. doi: 10.1016/j.ejso.2015.04. 005.

12. Sugarbaker PH. Peritonectomy procedure. Ann Surg 1995; 221 (1): 29–42. doi: 10.1097/00000658-199501000-00004.

13. Riss S, Chandrakumaran K, Dayal S et al. Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking. Eur J Surg Oncol 2015; 41 (3): 392–395. doi: 10.1016/ j.ejso.2014.09.002.

14. Spiliotis J, Halkia E, de Bree E. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy – current perspectives. Curr Oncol 2016; 23 (3): 266–275. doi: 10.3747/co.23.2831.

15. Lansom J, Alzahrani N, Liauw W et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours. Indian J Surg Oncol 2016; 7 (2): 166–176. doi: 10.1007/s13193-015-0478-9.

16. Qu ZB, Liu LX. Management of pseudomyxoma peritonea. World J Gastroenterol 2006; 12 (38): 6124–6127. doi: 10.3748/wjg.v12.i38.6124.

17. Shaligram A. Management of peritoneal surface malignancies in laparoscopic era: a concise review. Int J Surg Oncol (NY) 2016; 1 (2): e05. doi: 10.1097/IJ9.000 0000000000005.

18. Moran B, Baratti D, Yan TD et al. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasm with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 2008; 98 (4): 277–282. doi: 10.1002/jso.21054.

19. MacArthur KM, Nicholl MB. Principles and innovations in peritoneal surface malignancy treatment. World J Oncol 2013; 4 (3): 129–136. doi: 10.4021/wjon 660w.

20. Kulu Y, Muller-Stich B, Büchler MW et al. Surgical treatment of peritoneal carcinomatosis: current treatment modalities. Langenbecks Arch Surg 2014; 399 (1): 41–53. doi: 10.1007/s00423-013-1144-8.

21. Halkia E, Gavriel S, Spilioti J. Management of peritoneal surface malignancy: a review of the recent literature. JBUON 2014; 19 (3): 618–626.

22. Saxon A, Yan TD, Chua TC et al. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2010; 17 (5): 1291–1301. doi: 10.1245/s10434-009-0875-9.

23. Iversen LH, Rasmussen PC, Hagemann-Madsen R et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. Colorectal Dis 2013; 15 (7): 365–372. doi: 10.1111/codi.12185.

24. Chua TC, Moran BJ, Sugarbaker PH et al. Early-and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30 (20): 2449–2456. doi: 10.1200/JCO.2011.39. 7166.

25. Delhorme JB, Honoré C, Benhaim L et al. Long-term survival after aggressive treatment of relapsed serial or distant pseudomyxoma peritonei. Eur J Surg Oncol 2017; 43 (1): 159–167. doi: 10.1016/j.ejso.2016.08.021.

26. Kirby R, Liauw W, Zhao J et al. Quality of life study following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei including redo procedures. Int J Surg Oncol 2013; 2013: 461041. doi: 10.1155/2013/461041.